Foresee Pharmaceuticals Co., Ltd. 6576.TWO Stock
Foresee Pharmaceuticals Co., Ltd. Price Chart
Foresee Pharmaceuticals Co., Ltd. 6576.TWO Financial and Trading Overview
Foresee Pharmaceuticals Co., Ltd. stock price | 95.3 TWD |
Previous Close | 82.8 TWD |
Open | 82.8 TWD |
Bid | 83.1 TWD x 0 |
Ask | 83.2 TWD x 0 |
Day's Range | 82.7 - 83.9 TWD |
52 Week Range | 69.5 - 137.5 TWD |
Volume | 279.71K TWD |
Avg. Volume | 799.55K TWD |
Market Cap | 10.09B TWD |
Beta (5Y Monthly) | 1.461986 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.5 TWD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 124.56 TWD |
6576.TWO Valuation Measures
Enterprise Value | 9.34B TWD |
Trailing P/E | N/A |
Forward P/E | 143.44827 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 38.368305 |
Price/Book (mrq) | 13.179153 |
Enterprise Value/Revenue | 35.533 |
Enterprise Value/EBITDA | -19.495 |
Trading Information
Foresee Pharmaceuticals Co., Ltd. Stock Price History
Beta (5Y Monthly) | 1.461986 |
52-Week Change | -37.034% |
S&P500 52-Week Change | 20.43% |
52 Week High | 137.5 TWD |
52 Week Low | 69.5 TWD |
50-Day Moving Average | 90.49 TWD |
200-Day Moving Average | 95.23 TWD |
6576.TWO Share Statistics
Avg. Volume (3 month) | 799.55K TWD |
Avg. Daily Volume (10-Days) | 410K TWD |
Shares Outstanding | 121.25M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 35.40% |
% Held by Institutions | 3.39% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -201.41% |
Operating Margin (ttm) | -198.91% |
Gross Margin | 80.60% |
EBITDA Margin | -182.27% |
Management Effectiveness
Return on Assets (ttm) | -24.66% |
Return on Equity (ttm) | -54.091% |
Income Statement
Revenue (ttm) | 262.93M TWD |
Revenue Per Share (ttm) | 2.23 TWD |
Quarterly Revenue Growth (yoy) | -57.59% |
Gross Profit (ttm) | 275.97M TWD |
EBITDA | -479252000 TWD |
Net Income Avi to Common (ttm) | -529585984 TWD |
Diluted EPS (ttm) | -4.32 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 487.42M TWD |
Total Cash Per Share (mrq) | 4.12 TWD |
Total Debt (mrq) | 37.41M TWD |
Total Debt/Equity (mrq) | 5.01 TWD |
Current Ratio (mrq) | 9.726 |
Book Value Per Share (mrq) | 6.313 |
Cash Flow Statement
Operating Cash Flow (ttm) | -352432000 TWD |
Levered Free Cash Flow (ttm) | -383508512 TWD |
Profile of Foresee Pharmaceuticals Co., Ltd.
Country | Taiwan |
State | N/A |
City | Taipei |
Address | No. 19-3, Sanchong Road |
ZIP | 115 |
Phone | 886 2 7750 0188 |
Website | https://www.foreseepharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is based in Taipei, Taiwan.
Q&A For Foresee Pharmaceuticals Co., Ltd. Stock
What is a current 6576.TWO stock price?
Foresee Pharmaceuticals Co., Ltd. 6576.TWO stock price today per share is 95.3 TWD.
How to purchase Foresee Pharmaceuticals Co., Ltd. stock?
You can buy 6576.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Foresee Pharmaceuticals Co., Ltd.?
The stock symbol or ticker of Foresee Pharmaceuticals Co., Ltd. is 6576.TWO.
Which industry does the Foresee Pharmaceuticals Co., Ltd. company belong to?
The Foresee Pharmaceuticals Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Foresee Pharmaceuticals Co., Ltd. have in circulation?
The max supply of Foresee Pharmaceuticals Co., Ltd. shares is 135.93M.
What is Foresee Pharmaceuticals Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Foresee Pharmaceuticals Co., Ltd. PE Ratio is now.
What was Foresee Pharmaceuticals Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Foresee Pharmaceuticals Co., Ltd. EPS is -7.5 TWD over the trailing 12 months.
Which sector does the Foresee Pharmaceuticals Co., Ltd. company belong to?
The Foresee Pharmaceuticals Co., Ltd. sector is Healthcare.